Bone recurrence in early breast cancer patients: The paradox of aromatase inhibitors induced bone resorption.

Breast Disease
Francesco PaveseKatia Cannita

Abstract

Despite the increase in chances of cure for early breast cancer (EBC) patients, approximately 20-45% of them will experience a disease recurrence, particularly bone metastases in 60-80% of cases, which occur more frequently in luminal subtypes. Endocrine therapy (ET) has always been the milestone of adjuvant treatment for hormone receptor-positive EBC patients, leading to indubitable reduction of disease recurrence risk. However, adjuvant aromatase inhibitors (AIs) therapy may promote a progressive decrease in bone mineral density (BMD), which can lead to osteoporosis. The increased bone resorption associated with osteoporosis may provide fertile soil for cancer growth and accelerate the development of bone metastases. In this single-institution cohort study, we performed a retrospective analysis of "luminal-like" EBC patients who experienced bone recurrence after a subsequent disease free interval. The aim of the study was to evaluate the median time to skeletal recurrence (TSkR). 143 patients experienced bone recurrence. Median TSkR was 54 months (95%CI: 45-65). Among patients who received adjuvant AIs median TSkR was 35 months (95%CI: 25-54), while among patients who did not was 61 months (95%CI: 50-80) (HR = 1.45 [95%CI: 0....Continue Reading

References

Jan 16, 1999·Journal of the National Cancer Institute·T G KarrisonP Meier
Jan 28, 2003·Cancer·Sanna-Maria Käkönen, Gregory R Mundy
Jul 11, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edith A PerezPaul E Goss
Sep 12, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J GeislerJ Paolini
May 26, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hagen KenneckeKaren Gelmon
Jul 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harold J BursteinUNKNOWN American Society of Clinical Oncology
May 20, 2011·Nature Reviews. Cancer·Katherine N WeilbaecherLaurie K McCauley
Jun 7, 2011·The Lancet Oncology·Michael GnantUNKNOWN Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria
Oct 15, 2011·The New England Journal of Medicine·Robert E ColemanUNKNOWN AZURE Investigators
Nov 22, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Tingting YanJinsong Lu
Aug 7, 2013·Yonsei Medical Journal·Sung Gwe AhnHy-De Lee
Apr 2, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Penelope D OttewellIngunn Holen
May 8, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Laura E Wright, Theresa A Guise
Jun 5, 2015·Lancet·Michael GnantUNKNOWN Austrian Breast and Colorectal Cancer Study Group
Apr 20, 2018·Annals of Surgical Oncology·Armando E GiulianoGabriel N Hortobagyi
Apr 17, 2019·The Journal of Endocrinology·Sabashini K RamchandMathis Grossmann

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.